Gregory Matechak, MD
Family Medicine · Rockmart, GANPI 1851492672
Payments from drug & device makers
Across 91 payments — averaging $16.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$222
- Amgen$205
- Lilly USA, LLC$189
- AbbVie$180
- Novo Nordisk$152
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$105
- plus $464 from 16 others
What the payments were for
- Food & beverage$1,516100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 14 | $222 |
| Amgen(2 entities) | 11 | $205 |
| Lilly USA, LLC | 12 | $189 |
| AbbVie | 10 | $180 |
| Novo Nordisk | 10 | $152 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $105 |
| Idorsia Pharmaceuticals US Inc | 4 | $75 |
| Abbott | 3 | $52 |
| Exact Sciences | 3 | $46 |
| IBSA Pharma Inc. | 3 | $42 |
| GSK | 2 | $41 |
| Boehringer Ingelheim | 2 | $29 |
| Pfizer | 2 | $29 |
| Genentech USA, Inc. | 1 | $22 |
| Biotronik NRO, Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $19 |
| Optinose US, Inc. | 1 | $17 |
| Antares Pharma, Inc. | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Johnson & Johnson | 1 | $12 |
How this compares
$1,516 in reported general payments places this provider in the 65th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 58 | $71,505 |
| MounjaroTirzepatide | 63 | $67,448 |
| EliquisApixaban | 24 | $41,319 |
| OzempicSemaglutide | 27 | $37,165 |
| XareltoRivaroxaban | 12 | $17,191 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $14,355 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $9,317 |
| SymbicortBudesonide/Formoterol Fumarate | 18 | $5,915 |
| SynthroidLevothyroxine Sodium | 42 | $2,783 |
| Levothyroxine Sodium | 224 | $2,634 |
| Gabapentin | 115 | $2,362 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 46 | $2,226 |
| Atorvastatin Calcium | 244 | $1,321 |
| Estradiol | 49 | $1,293 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 57 | $1,270 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $29 | $71,50558 claims |
| Lilly USA, LLCMounjaro | $189 | $67,44863 claims |
| PfizerEliquis | $29 | $41,31924 claims |
| Novo NordiskOzempic | $152 | $37,16527 claims |
| Johnson & JohnsonXarelto | $12 | $17,19112 claims |
| GSKTrelegy Ellipta | $41 | $14,35515 claims |
| AstraZenecaSymbicort | $222 | $5,91518 claims |
| AbbVieSynthroid | $180 | $2,78342 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Rockmart
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
- John LentzSnellville$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.